GLP-1 and Antidepressants: Which Ones Actually Interact

By the Weight Loss Provider Guide Research Team · Last verified: August 7, 2026

Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers. This page contains affiliate links to some providers. That money never changes what a drug label says, and it did not change a single line below.

The short answer

For most people asking about GLP-1 and antidepressants, the current labels in this guide do not prohibit the pair. We checked the current U.S. labels for Wegovy, Ozempic injection, Rybelsus and Ozempic tablets, Zepbound, Mounjaro, Saxenda, and Foundayo. Not one of those labels lists an antidepressant as a reason you cannot take the drug.

Four checks change the plan. Only four:

1. You take an oral semaglutide tablet — Wegovy, Rybelsus, or Ozempic tablets. Then the time you swallow your antidepressant may have to move. This is the most common real conflict on this page.
2. You take Foundayo. A few mood medicines — nefazodone, St. John's wort, and carbamazepine — can change your Foundayo plan. This is brand new as of April 2026.
3. You take lithium, a tricyclic such as nortriptyline, or delayed-release Cymbalta. These need a specific conversation, and we'll show you exactly what to ask.
4. You're actually looking at Contrave, Qsymia, or phentermine, not a GLP-1. Contrave is off-limits with Wellbutrin or an MAOI. Qsymia and phentermine are also off-limits with an MAOI.

If none of those four is you, the label review gives you a reassuring starting point. You still need your own full medication list checked.

Now here's the part most pages skip, and it's the reason we built this page instead of another "generally safe, ask your doctor" article:

No antidepressant appears in the dedicated drug-interaction studies listed in the GLP-1 labels we reviewed. Not one.

We'll show you the full list of what was tested in a minute. That gap doesn't make the combination dangerous. It makes the details matter more — your exact drug, your exact form, your exact morning. That's what the rest of this page is for.

⚠️ If you are having thoughts of hurting yourself, please stop reading and get help now. In the U.S., call or text 988 for the Suicide & Crisis Lifeline. If you're in immediate danger, call 911.

Find your situation in 15 seconds

The four lanes: which question are you actually asking?

Here's why every other page on this topic feels vague. "Can I take a GLP-1 with my antidepressant" isn't one question. It's four. And they have four totally different answers.

Once you know which lane you're in, this gets simple.

Most people who land here think they're asking Lane 1. Most of them are actually in Lane 2 or Lane 3.

What we verified for this GLP-1 and antidepressants guide

We want you to know exactly what's behind every claim on this page, because a lot of health content online is one writer copying another writer.

What we read, line by line:

• The current U.S. prescribing information for Wegovy injection and tablets (revised 02/2026), Rybelsus and Ozempic tablets (revised 01/2026), Ozempic injection (revised 05/2026), Zepbound (revised 02/2026), Mounjaro (revised 01/2026), Saxenda (revised 02/2026), and Foundayo (initial approval 04/2026) — especially the Contraindications, Warnings, Drug Interactions, Dosage, and Clinical Pharmacology sections
• FDA's current examples of drugs that inhibit or induce CYP3A4
• The current labels for nortriptyline, duloxetine (Cymbalta), bupropion, Contrave, Qsymia, phentermine, and venlafaxine
• The SURMOUNT-1 protocol and the semaglutide STEP trial records, to see which mental-health medicines and conditions were excluded
• Published case reports and the main studies on antidepressants and GLP-1 weight outcomes
• Current provider pricing and program pages for the one commercial comparison near the end

Our cross-label check, verified August 7, 2026

What we did not do:

• We did not test anything ourselves
• We are not doctors, and this page can't tell you whether your combination is right for you
• We did not check every antidepressant ever sold against every GLP-1 product ever sold
• We did not independently test provider response times, care quality, or whether an insurer will cover your prescription

Anywhere the evidence stops, we say so. We'd rather show you the seam than paper over it.

Can you take GLP-1 and antidepressants together?

Answer capsule: In most cases, the current labels we reviewed do not prohibit the combination. No antidepressant appears in the contraindications section of Wegovy, Rybelsus or Ozempic tablets, Ozempic injection, Zepbound, Mounjaro, Saxenda, or Foundayo. The practical concerns are oral-semaglutide timing, Foundayo's CYP3A4 rules, overlapping side effects, vomiting, and a short list of medicines that already need close monitoring.

There's a difference between two things that get mushed together constantly, and once you see it you'll never unsee it.

A direct interaction is when two drugs chemically fight. One blocks the other from being broken down, or speeds it up, and the amount in your blood changes. This is what a drug interaction checker is looking for.

An indirect concern is everything else. Your stomach empties slower, so a pill gets absorbed later. You throw up, so the pill may not have stayed down. You're nauseated, so you skip a dose. None of that is a chemical fight. All of it can still cause a problem.

Here's the thing: the direct interaction question is mostly answered for the peptide GLP-1 products, and the answer is good. Semaglutide, tirzepatide, and liraglutide are peptide medicines. The semaglutide labels describe very low potential to inhibit or induce CYP enzymes, the tirzepatide labels describe low potential, and liraglutide is broken down like a large protein rather than through one specific organ pathway.

Foundayo is the exception to that simple sentence. Orforglipron is a small molecule and a CYP3A4 substrate. It gets its own section because some other medicines can change Foundayo's level.

The indirect stuff is where the real answers live. And that's what most pages fail to sort out for you.

The thing we found in the labels

We went looking for the dedicated drug-interaction studies. Across the semaglutide labels we reviewed, the listed studies included:

Levothyroxine · lisinopril · warfarin · metformin · digoxin · ethinyl estradiol · levonorgestrel · furosemide · rosuvastatin · omeprazole

Foundayo's label lists studies with:

Clarithromycin · verapamil · carbamazepine · efavirenz · modafinil · cyclosporine · quinidine · esomeprazole · simvastatin · atorvastatin · rosuvastatin · midazolam · digoxin · acetaminophen

Count the antidepressants. There are none.

No antidepressant appears in the dedicated interaction-study lists in those labels.

Now — that's not alarming. Drug companies focus formal interaction studies on medicines most likely to expose a known pathway problem. But "no label-listed interaction" and "this exact antidepressant was put through a dedicated interaction study" are two different sentences. This page keeps those sentences separate.

That's why the rest of the page walks you through your specific medicine instead of handing you a green checkmark.

Will a GLP-1 change antidepressant blood levels? (Lane 1)

Answer capsule: Usually not through a liver-enzyme interaction. Semaglutide and tirzepatide have very low or low potential to inhibit or induce cytochrome P450 enzymes, while liraglutide is broken down like a large protein. Foundayo has separate CYP3A4 rules. Every product in this review can also slow stomach emptying, which can matter for oral medicines with a narrow safe range or a need for clinical monitoring.

Let's do the mechanism in plain words, because you don't need a pharmacology degree for this.

Your stomach hands pills down to your gut, which is where most of them get absorbed. GLP-1 medicines slow that handoff down. That's part of how they work — food sits longer, and you may feel full longer.

Most antidepressants are not dosed by a blood level. A change in how fast a pill reaches the gut does not automatically mean a dangerous change in how much drug reaches your bloodstream.

A few medicines do need closer watching. Those are drugs where the amount in your blood is already part of the treatment plan, or where dehydration, kidney changes, or missed doses can move the risk fast.

The Wegovy label tells clinicians to consider more clinical or laboratory monitoring for oral drugs with a narrow therapeutic index or drugs that require clinical monitoring. Zepbound likewise tells clinicians to monitor oral drugs that depend on threshold concentrations and narrow-window drugs such as warfarin.

"Narrow therapeutic index" just means the useful range is tight. Too little may not work. Too much may cause harm. The gap is small.

Neither label names an antidepressant. So we did the work of sorting the medicines on this page by what is actually monitored.

The narrow-window shortlist

If you're in the bottom row, you're most people. That's the reassuring answer — but now it comes with a reason instead of a shrug.

If you take lithium, read this part

Lithium isn't technically an antidepressant, but a lot of people take it alongside one, and it is the clearest published harm signal we found on this whole topic.

Doctors at the Mayo Clinic reported three cases involving higher lithium levels after patients started semaglutide. Two developed toxicity despite stable kidney function and no changes in their other medicines. In the third case, a preemptive dose reduction reduced the harm, but the level still rose more than expected. A separate 2026 case report describes lithium toxicity in a 23-year-old after switching from semaglutide to tirzepatide.

Here's what may be happening, and it is not one simple chemical fight. The published authors point to several possible routes: lower fluid and food intake, vomiting or diarrhea, kidney changes, and delayed stomach emptying. Dehydration matters, but it is not the only proposed mechanism.

What to do: Ask for your baseline lithium level, kidney function, and hydration status to be reviewed before the GLP-1 starts. Ask your lithium prescriber how soon they want the level repeated after a start, a switch, and each GLP-1 dose increase. There is no one evidence-based "4 to 6 week" rule for every patient. Ask for a sick-day plan too — meaning, what do you do about lithium on a day you cannot keep fluids down.

That's a short conversation that can prevent a serious problem.

More on the fluid side of this: GLP-1 electrolytes and dehydration: what to drink and when to call.

If you take a tricyclic (nortriptyline, amitriptyline, imipramine)

Good news: this is a monitoring question, not a blanket ban.

Nortriptyline is the clearest example. Its current label says that when doses go above 100 mg per day, plasma levels should be monitored and kept in the range of 50 to 150 ng/mL. That's not new advice because of a GLP-1 — that's just how the drug is managed at those doses.

Do not assume your level is already being watched. Tell whoever manages the tricyclic that you're starting or increasing a GLP-1. Ask whether your exact medicine and dose call for a level or a symptom check after the change.

Nothing dramatic. Just don't let it slip through.

If you take delayed-release Cymbalta (duloxetine)

This one is genuinely underappreciated, and it comes straight from Cymbalta's own label — not from a published GLP-1 interaction study.

Cymbalta capsules have an enteric coating. That's a shell designed to protect duloxetine from stomach acid until the capsule reaches farther down the digestive tract.

Cymbalta's prescribing information says there is no information about how altered gastric motility affects that coating and advises caution in conditions that may slow stomach emptying.

What this is not: it is not a published rule that GLP-1s break the coating, and it is not a reason to avoid either drug.

What it is: a legitimate reason to raise your hand. If you take delayed-release duloxetine and you're starting a GLP-1, here's the exact question:

"I take delayed-release duloxetine. Does my GLP-1 change how you want me to take it or monitor it?"

And one hard rule from the label: swallow the capsule whole. Do not chew, crush, or open it.

Does a GLP-1 change when you take your antidepressant? (Lane 2)

Answer capsule: Only the oral semaglutide tablets in this review have the 30-minute morning wall: Wegovy tablets, Rybelsus, and Ozempic tablets. Take the tablet on an empty stomach in the morning with no more than 4 ounces of water, then wait at least 30 minutes before food, another drink, or any other oral medicine. Foundayo and the injections do not have that rule.

This is the one that will actually change somebody's morning, and it was hiding in plain sight in FDA documents.

The current Wegovy tablet label and the current combined Rybelsus/Ozempic-tablet label give the same core instruction: take the oral semaglutide tablet first, with water only, and wait at least 30 minutes before taking another oral medicine.

Read that last part again. Before taking another oral medicine.

That's your antidepressant. If you take it in the morning, it moves.

Here's why this matters and why a basic interaction checker may miss it: the checker compares two molecules. It may not account for a dosing wall around one formulation. So you can get "no interactions found," which answers the chemistry question but not the clock question.

Which antidepressants have to move

Your new morning, in four steps

1. Wake up. Don't eat or drink anything yet.
2. Take your Wegovy, Rybelsus, or Ozempic tablet with up to 4 ounces of water. Water only — not coffee, not juice, not with your other pills.
3. Wait at least 30 minutes.
4. Then have coffee, breakfast, and your other oral medicines as directed.

That's it. That's the whole adjustment.

And if you mess it up once? A shorter wait can reduce oral semaglutide absorption. Do not take another tablet to make up for it. Follow the label for the next dose, and call your pharmacist if you are unsure or if the timing mistake keeps happening.

One thing not to do: don't move your antidepressant to bedtime on your own. Some can affect sleep. Some can make you dizzy. If moving it makes more sense than waiting 30 minutes, that's a call for your pharmacist or prescriber.

If you're on a shot, none of this pill-spacing rule applies to you

Wegovy, Ozempic, Zepbound, and Mounjaro are weekly injections. Saxenda is a daily injection. None has the oral-semaglutide 30-minute rule involving other medicines.

You can take your antidepressant at the time printed on your bottle. The injection labels still warn that slower stomach emptying can affect some oral drugs, so lithium and other closely monitored medicines still belong in Lane 1.

You can skip to Lane 3.

Which mood medicines can change your Foundayo dose?

Answer capsule: Foundayo (orforglipron), approved in April 2026, is a small-molecule GLP-1 drug and a CYP3A4 substrate. Its label caps the maximum dose at 9 mg instead of 17.2 mg with a strong CYP3A4 inhibitor and says to avoid strong CYP3A4 inducers. Nefazodone, St. John's wort, and carbamazepine are the three mood-related products that clearly land in those strong-agent groups.

This section did not exist before Foundayo was approved. It exists now because the old one-sentence answer about GLP-1 metabolism no longer covers every product.

Here's the background in one paragraph.

The semaglutide, tirzepatide, and liraglutide products in this guide are peptides. They are not cleared through the same CYP enzyme routes that handle many small-molecule medicines.

Foundayo is different. It's a small molecule, not a peptide. Foundayo's label says orforglipron is metabolized mainly by CYP3A4 and is a substrate of CYP3A4 and CYP2J2.

Think of CYP3A4 as a lane that helps carry drugs out of your body. Some medicines slow that lane, so Foundayo levels rise. Some speed it up, so Foundayo levels fall.

Foundayo's label handles this with actual dose rules:

• Strong CYP3A4 inhibitor: maximum Foundayo dose drops from 17.2 mg to 9 mg
• Strong CYP3A4 inducer: avoid the combination
• Moderate CYP3A4 inducer: monitor whether Foundayo is working and increase the dose if the prescriber decides it is needed

And Lilly's own interaction data shows how big this can get. Carbamazepine — a strong inducer — cut orforglipron exposure by 82% by AUC and 55% by peak concentration. Clarithromycin, a strong inhibitor, raised exposure 3.5-fold by AUC and 1.9-fold by peak concentration.

Now cross that against the mood shelf

FDA's current CYP examples page puts three mood-related products in the strong categories that trigger Foundayo's label rules:

This is the first FDA-approved GLP-1 product in this review with label-based CYP3A4 dose rules that a mood medicine can trigger.

The St. John's wort problem

We want to put a box around this one.

St. John's wort is an herbal product. People take it for low mood. And it often gets left off medication lists, because people don't think of a supplement as a medicine.

FDA lists it as a strong CYP3A inducer, with strength that can vary by preparation. Foundayo's label says to avoid strong inducers. That means it can make Foundayo less effective.

If you take St. John's wort — or any herbal supplement — write it on your list. That's the entire ask.

The reassuring half of this

Foundayo did not inhibit or induce CYP2D6 in the label's in-vitro studies. CYP2D6 is one of the enzymes involved with several antidepressants.

Translation: the label does not point to a CYP2D6 enzyme interaction that raises or lowers Zoloft, Prozac, or Paxil. But Foundayo still delays stomach emptying, so do not turn that into a blanket promise that it can never affect an oral medicine.

FDA's current examples page lists fluvoxamine as a weak CYP3A inhibitor and notes a larger effect with one sensitive CYP3A substrate. Foundayo's 9 mg cap is written for strong inhibitors, so that cap does not follow from fluvoxamine alone. Still put fluvoxamine on the list and let the prescriber check the whole plan.

Will GLP-1 and antidepressant side effects stack? (Lane 3)

Answer capsule: They can, especially when one medicine is started or a dose goes up. Nausea, vomiting, loose stools, constipation, dizziness, and fatigue can come from a GLP-1, an antidepressant, low food or fluid intake, or more than one of those at once. The useful move is to track timing instead of guessing.

This is the lane most people are actually in, and it's the one that gets the least useful advice.

The timing trick that helps tell them apart

This is the most useful thing in this section.

GLP-1 side effects often follow the GLP-1 calendar. They may show up after a first dose or a dose increase and ease as your body adjusts. The exact day pattern is not the same for everyone.

Antidepressant side effects often follow an antidepressant start or dose change. Some improve over the next days or weeks. Some need a medication change.

So write down the dates. If symptoms repeat after the GLP-1 dose, that pattern matters. If they began right after your antidepressant changed and stay steady, that matters too.

Which leads to one rule: do not change either medicine on your own. When it is clinically possible, ask the two prescribers to avoid making both changes on the same day. If both must change, write down what changed and when so the pattern is not lost.

Can a GLP-1 cause serotonin syndrome with my antidepressant?

No class-wide GLP-1-and-antidepressant serotonin-syndrome interaction appears in the current labels we reviewed. GLP-1 receptor agonists are not serotonergic drugs.

Serotonin syndrome happens when serotonin-raising medicines or substances stack up. The GLP-1 itself is not the usual driver.

One honest caveat: serotonin syndrome is real, and it comes from other combinations. If you take an SSRI or SNRI plus tramadol, linezolid, an MAOI, certain migraine medicines, or certain supplements, your full list needs a review — with or without a GLP-1 in the picture.

Dehydration is the underrated one

Most of the scary stuff on this page traces back to one thing: fluid loss.

Vomiting and diarrhea drain you. Low fluid can raise lithium risk. Low fluid makes dizziness worse. Low fluid plus low food can look like a return of fatigue or low mood.

During a start or dose increase, take small, regular sips and follow the fluid plan your clinician gave you. If you have heart failure, kidney disease, or another reason to limit fluids, do not force extra fluid without asking your clinician.

Full practical guide: GLP-1 electrolytes and dehydration: what to drink and when to call.

What if you throw up after taking your antidepressant?

Answer capsule: Do not automatically retake the dose. Whether a repeat dose is right depends on the exact medicine, its release form, how much time passed, and whether the pill was visible. A double dose of some antidepressants carries its own risk. Call the dispensing pharmacist for drug-specific instructions.

This is one of the most practical questions on the whole topic, and almost nobody answers it.

Here's what's going on. GLP-1s can cause vomiting, especially when treatment starts or a dose increases. Your antidepressant is a pill. Sooner or later, the two may meet.

Do not just take another one.

We know that's the instinct. Here's why it's the wrong move:

• Some antidepressants are risky in a double dose. Bupropion is the clearest example because its seizure risk rises with dose.
• Some are extended-release or delayed-release. A doubled ER or DR dose does not behave like two regular doses.
• You often cannot tell how much was absorbed. Seeing a whole pill is useful information, but it still does not create one rule for every product.
• There is no universal "if it's been X minutes, retake it" rule. Any page that gives you one rule for every antidepressant is guessing.

What to do instead — in order:

1. Call the pharmacy that filled it. Pharmacists answer this kind of question, and they can see the exact medicine, dose, and release form.
2. Tell them three things: the exact drug name from the bottle, how long after taking it you threw up, and whether you saw the pill.
3. Write it down. Date, time, which medicine, and what the pharmacist told you to do. Your prescriber needs the pattern, not a fuzzy one-off story.

And if it keeps happening: repeated vomiting is not just a medication-timing problem. It puts you at risk for dehydration, kidney injury, and missed antidepressant doses. Call the GLP-1 prescriber promptly. The dose or escalation pace may need review. That is a normal treatment adjustment, not a failure.

Do antidepressants make GLP-1 weight loss less effective? (Lane 4)

Answer capsule: No universal blocking effect has been established. A 2022 retrospective study found less weight loss in two antidepressant groups using GLP-1 receptor agonists, while a published post-hoc analysis of the STEP trials found substantial semaglutide weight loss in people taking antidepressants at baseline. The studies used different designs and answer different questions.

This is the fear behind a lot of searches: "Am I going to pay $300 a month for something my Lexapro cancels out?"

Let's put the studies on the table and then do the math nobody does.

The arithmetic nobody does

Take the Petimar numbers. The largest average difference in that table was 0.41 kg over six months compared with sertraline.

That's under one pound as a between-drug average difference. It is not the total weight gained by everyone who takes Lexapro, and it is not a ceiling on what one person can experience.

Meanwhile, semaglutide 2.4 mg in STEP 1 produced about 15% average body-weight reduction. On a 220-pound person, 15% is roughly 33 pounds.

Those numbers come from different studies, so you cannot divide one by the other and call it a personal forecast. But they do kill the simple claim that a small average antidepressant difference automatically cancels a GLP-1.

So what's the honest conclusion?

An antidepressant does not appear to create a universal block on GLP-1 weight loss. It can still be one factor among many — along with the GLP-1 dose, how long you stay on treatment, side effects, missed doses, sleep, food intake, movement, other medicines, and depression itself.

If you lose weight more slowly than your friend, don't stop your Zoloft and don't pick one villain. Ask the prescriber to review the full picture.

What if the antidepressant is what made me gain the weight?

Answer capsule: In the largest head-to-head study, average six-month weight differences between common first-line antidepressants were under half a kilogram relative to sertraline. That is not a reason to stop a medicine that is working. It also does not erase a person's larger individual weight change, which deserves a full review.

We're going to be blunt here, because this is where people make expensive mistakes.

A lot of readers land on this page carrying a specific resentment: "I was fine, then I went on Cymbalta, then I gained 30 pounds."

That feeling is real and the timing might be real. But here's the honest picture from the biggest study we have:

Petimar J et al., Annals of Internal Medicine, 2024. 183,118 adults.

Escitalopram, paroxetine, and duloxetine users were about 10% to 15% more likely than sertraline users to gain at least 5% of their starting weight. Bupropion users were about 15% less likely.

Notice what this table actually says: it compares average differences between medicines. It does not say that a 30-pound individual change is fake. It says a population average cannot prove that one drug alone caused every pound.

Large weight changes can have more than one cause: the medicine, recovery of appetite as depression improves, sleep, activity, another medicine, a health condition, or several of those at once.

Should you switch antidepressants to lose more weight?

Do not switch or stop an antidepressant based on this page.

We're going to disqualify hard here, because it's the right thing to do. If your antidepressant is working, trading it away for a small average weight difference can be a bad deal. Stopping or changing it can bring withdrawal symptoms and a return of depression or anxiety.

Bupropion looks best on this one weight table. It is also wrong for plenty of people — it is contraindicated in people with a seizure disorder and in people with a current or prior diagnosis of anorexia nervosa or bulimia. It can also feel too activating for some people.

The right move: if weight is genuinely affecting your health, add a conversation about weight treatment and the full medication list. Don't subtract the thing that's working without a prescriber-led plan.

If you have a history of disordered eating, read this first: GLP-1 contraindications and the checks that need a clinician.

Were people like you even in the studies?

Answer capsule: Not always. The SURMOUNT-1 tirzepatide protocol excluded recent use of eleven named medications considered likely to cause weight gain. Five were antidepressants: imipramine, amitriptyline, mirtazapine, paroxetine, and phenelzine. The protocol explicitly permitted SSRIs other than paroxetine.

Here's the part of this topic that other pages skip, and it's the reason we think you should trust the rest of what's on this page.

The big tirzepatide weight-loss trial — SURMOUNT-1 — screened people out if they'd recently taken any of these:

imipramine · amitriptyline · mirtazapine · paroxetine · phenelzine · chlorpromazine · thioridazine · clozapine · olanzapine · valproic acid derivatives · lithium

"Note: Selective serotonin reuptake inhibitors other than paroxetine are permitted."

Five antidepressants. Named. Excluded.

The semaglutide STEP 1 trial did not use that same named antidepressant list, but it had its own psychiatric eligibility rules, including exclusions tied to recent major depressive disorder and suicidality.

In plain words: if you take Paxil, Remeron, or a tricyclic, the direct trial data on people using that exact medicine is thinner than it is for someone taking Zoloft. That's a real gap and we're not going to pretend otherwise.

And here's the other half of that. The SURMOUNT-1 protocol placed those drugs in a list of medicines considered likely to cause weight gain. That makes the exclusion look like a way to keep medication-driven weight change from muddying the weight-loss result. It does not prove the combinations were unsafe.

Published case reports found in this review focus on lithium, not Paxil or Remeron.

So: less trial data is a reason to check in with your prescriber. It is not, by itself, a reason to skip treatment.

Full breakdown: GLP-1 clinical trial exclusion criteria across 17 pivotal trials.

Find your medicine

Now the lookup. Here's what applies to each group specifically.

Can you take a GLP-1 with an SSRI (Zoloft, Lexapro, Prozac, Celexa, Paxil)?

Answer capsule: No SSRI appears as a contraindication in the current GLP-1 labels reviewed here. SSRIs are not normally managed with routine blood levels. The practical issues are overlapping stomach side effects and, for Wegovy, Rybelsus, or Ozempic tablets, the 30-minute morning gap before any other oral medicine.

Zoloft (sertraline). No pill-spacing rule with a shot. If you take it in the morning and you're on an oral semaglutide tablet, it moves until after the 30-minute wait. Nausea can overlap early — sertraline can cause stomach upset after a start or dose change, and so can GLP-1 treatment.

Lexapro (escitalopram). Same timing picture. Worth knowing: in the Petimar study, escitalopram had the largest six-month average weight difference in the table — 0.41 kg more than sertraline, not 0.41 kg of total weight gain for every user. That is not a reason to switch.

Prozac (fluoxetine). Often taken in the morning, which can create an oral-semaglutide timing conflict. Fluoxetine has a long half-life, but that is not permission to skip, move, or double doses on your own.

Celexa (citalopram). Same clock rule. If you take it at night, the morning oral-semaglutide wall does not touch it.

Paxil (paroxetine). This is the SSRI singled out in the SURMOUNT-1 exclusion list. Mention that to your prescriber — not as a danger sign, but as a "there's less direct trial data here" note. Paroxetine also had a small average weight difference relative to sertraline in the Petimar study.

Can you take a GLP-1 with an SNRI (Effexor, Cymbalta, Pristiq)?

Answer capsule: No SNRI appears as a contraindication in the current GLP-1 labels reviewed here. Duloxetine warrants one extra conversation because its delayed-release capsule uses an enteric coating and its own label advises caution when stomach emptying may be slow.

Effexor XR (venlafaxine). Extended-release, often taken with food. If you're on an oral semaglutide tablet and take Effexor in the morning, it moves until after the 30-minute wait. Important: venlafaxine can cause discontinuation symptoms when doses are missed. If nausea is making you skip it, that's a call, not a wait-and-see.

Pristiq (desvenlafaxine). Same oral-semaglutide timing rule if you take it in the morning. Do not crush or split an extended-release tablet.

Cymbalta (duloxetine). See the enteric-coating section above. One extra question, and swallow the capsule whole.

Can you take a GLP-1 with Wellbutrin (bupropion)?

Answer capsule: Bupropion does not appear as a contraindication in the GLP-1 labels reviewed here and is not normally managed by blood levels. Its own restrictions still matter: bupropion is contraindicated with seizure disorder, current or prior anorexia nervosa or bulimia, and another bupropion-containing product such as Contrave.

Wellbutrin gets asked about more than any other antidepressant on this topic, for two reasons: it's the one linked to the least average weight gain in the Petimar comparison, and it's the one inside Contrave.

With a GLP-1 shot: no 30-minute pill-spacing rule. With an oral semaglutide tablet: wait at least 30 minutes before the Wellbutrin. Bupropion XL is often a morning drug, so that gap will apply to many people.

Three things that matter independent of your GLP-1:

1. Seizure disorder. Bupropion is contraindicated in people with a seizure disorder. Poor intake, vomiting, or other seizure-risk factors belong in the same conversation.
2. Eating-disorder history. Bupropion is contraindicated in people with a current or prior diagnosis of anorexia nervosa or bulimia.
3. You cannot take Contrave with it. Contrave contains bupropion, and its label contraindicates use with any other bupropion-containing product — Wellbutrin, Wellbutrin SR, Wellbutrin XL, Aplenzin, or Zyban. More on that below.

One claim we're not going to repeat: you'll see pages describing bupropion and GLP-1s as "synergistic" for weight loss. The studies reviewed here do not establish that. Bupropion had a small average advantage over sertraline in one antidepressant study. That's a different sentence.

Can you take a GLP-1 with mirtazapine (Remeron) or trazodone?

Answer capsule: Neither mirtazapine nor trazodone appears as a contraindication in the GLP-1 labels reviewed here. Both are often taken at bedtime, which avoids the oral-semaglutide morning window. Mirtazapine was among the medicines excluded from SURMOUNT-1's recent-use list.

Mirtazapine (Remeron). It is often taken at bedtime, so the oral-semaglutide morning rule may not touch it. It can increase appetite and weight, which is often exactly why someone on it is reading this page. Two honest notes: it was excluded from SURMOUNT-1's recent-use list, so direct trial data is thinner. And no study in this review proves that a GLP-1 simply "cancels out" mirtazapine. The result is individual.

Trazodone. Often taken at bedtime, usually for sleep. No morning timing conflict if that is your prescribed time. Watch for dizziness stacking — trazodone can make some people lightheaded when they stand, and fluid loss from a GLP-1 can add to that.

Can you take a GLP-1 with a tricyclic antidepressant?

Answer capsule: Tricyclic antidepressants do not appear as contraindications in the GLP-1 labels reviewed here. But some tricyclic treatment plans use blood levels, and nortriptyline's label specifically calls for plasma monitoring above 100 mg/day. That puts certain patients in the monitoring group flagged by GLP-1 labels.

Covered in Lane 1. Short version: do not assume your level is already being checked. Make sure the person managing the tricyclic knows you started or increased a GLP-1 and ask whether your exact drug and dose need a level.

Also watch constipation. Tricyclics can cause it. GLP-1s can cause it. Together they can genuinely back you up. Follow your care plan for food, fluid, movement, and bowel medicine. Get prompt help for severe pain, vomiting, swelling, or inability to pass stool or gas.

Can you take a GLP-1 with an MAOI?

Answer capsule: An MAOI does not appear as a contraindication in the GLP-1 labels reviewed here. But MAOIs carry extensive restrictions with other medicines, supplements, and foods. Contrave, Qsymia, and phentermine are each contraindicated during MAOI use and for 14 days after stopping an MAOI.

If you're on phenelzine (Nardil), tranylcypromine (Parnate), isocarboxazid (Marplan), or selegiline, you already know your list is complicated. We're not going to give you a one-liner.

The GLP-1 itself is not the main concern found in this review. The concern is that MAOIs interact with a long list of things, and anything new in your routine — including over-the-counter nausea products you might reach for during GLP-1 side effects — needs to be checked.

Three specifics:

• Phenelzine was on the SURMOUNT-1 exclusion list.
• Contrave is contraindicated with MAOIs and requires at least 14 days between them.
• Qsymia and phentermine are also contraindicated with MAOIs and require a 14-day gap.

Bring your entire list — prescriptions, over-the-counter products, and supplements — to a pharmacist. Not a one-pair website checker.

Can you take a GLP-1 with lithium?

Covered fully in Lane 1. This is the clearest combination on this page with published case reports of harm. Ask for baseline lithium, kidney function, and hydration review, then a prescriber-set plan for more frequent lithium levels after starts, switches, and dose increases. Get a sick-day plan too.

Can you take a GLP-1 with St. John's wort?

Answer capsule: No CYP interaction is expected with the peptide GLP-1 products in this guide. With Foundayo, St. John's wort is the problem: FDA lists it as a strong CYP3A inducer, and Foundayo's label says to avoid strong inducers because they can reduce orforglipron exposure.

Covered in the Foundayo section. The single most important thing: write it on your list. Supplements count as medicines here.

Will starting a GLP-1 make my depression worse?

Answer capsule: In January 2026, FDA said its comprehensive review — including a meta-analysis of 91 placebo-controlled trials covering 107,910 patients — did not find an increased risk of suicidal thoughts or behavior with GLP-1 receptor agonists. FDA also found no increased signal for anxiety, depression, irritability, or psychosis. New or worsening mood symptoms still need a prompt call.

Short section on purpose. This is a whole topic of its own.

What FDA found: no increased risk of suicidal thoughts or behavior at the population level, and no increased signal for anxiety, depression, irritability, or psychosis. That's a large review and it's reassuring.

What it doesn't mean: it doesn't mean a new mood change should be ignored. Population data cannot tell you what is causing one person's symptoms. Low intake, fluid loss, poor sleep, the loss of food as a coping tool, another medicine, and depression itself can all be part of the picture.

FDA asked manufacturers to remove the suicidal-thoughts warning from the Saxenda, Wegovy, and Zepbound labels that contained it. The current Wegovy label checked for this page, revised February 2026, no longer carries that warning.

Report it if: your mood drops noticeably, you feel unusually flat or numb, your behavior changes, or you have thoughts of hurting yourself.

If you're not safe right now, call or text 988 (Suicide & Crisis Lifeline, U.S.). If you're in immediate danger, call 911.

For the wider safety screen: GLP-1 contraindications: who should not take one and who needs a closer review. If it feels more like fog than sadness, write down when it started and whether it follows a dose change, then report it if it is new or worsening.

What about Contrave and the other weight-loss drugs?

Answer capsule: Contrave is not the only non-GLP-1 weight-loss medicine with antidepressant restrictions. Contrave is contraindicated with another bupropion product and with MAOIs. Qsymia and phentermine are also contraindicated with MAOIs. Venlafaxine's label says combining it with weight-loss agents, including phentermine, is not recommended.

People say "weight loss drug" and mean "GLP-1." They're not the same thing, and on this topic the difference is the whole answer.

So if you're on Wellbutrin: Contrave is out, and the current GLP-1 labels reviewed here do not carry that same bupropion restriction.

If you're on an MAOI: Contrave, Qsymia, and phentermine are all out during treatment and for the label-required gap. Do not let anyone reduce that to "only Contrave interacts."

Who do you call, and when?

Answer capsule: Timing and retake questions belong to a pharmacist. Mood changes and prescription changes belong to the prescriber. Repeated vomiting, inability to keep fluids down, severe or lasting abdominal pain, a severe allergic reaction, collapse, or suicidal danger need prompt or emergency help.

The pharmacist row is the underused one. People sit on timing questions for three weeks waiting for an appointment when a short pharmacy call could solve it on day one.

What to bring to the conversation

Answer capsule: Bring a complete list of every medicine and supplement with exact names and release forms, the dates of recent dose changes, and a short baseline of your current mood, stomach symptoms, sleep, food, and fluid intake. Photos of the actual bottles beat memory.

Bring these

• Photos of every bottle. Not a list from memory. The label has the exact name, strength, and whether it is IR, SR, XL, ER, or DR — and that detail changes the answer.
• Supplements and over-the-counter products. Especially St. John's wort, and especially if you're considering Foundayo.
• The date your antidepressant last changed.
• The date your GLP-1 last changed — start, switch, or dose increase.
• A one-line symptom baseline. How is your mood, appetite, stomach, sleep, food intake, and fluid intake right now, before anything changes?

The seven questions worth asking

1. "Does anything I take need a blood level or kidney check while I'm starting this?"
2. "Is any of my medicine a morning pill that has to move?"
3. "If I get sick and can't keep fluids down, what do I do about [your medicine]?"
4. "If I throw up right after a dose, should I ever retake it — and who do I call first?"
5. "What mood changes do you want me to report, and how fast?"
6. "When is my first follow-up after I start or increase the GLP-1?"
7. "Who is coordinating this — you or my other prescriber?"

That last one matters more than people think. The most common real problem on this topic may not be chemistry. It's split care. Your primary care doctor or psychiatrist manages the antidepressant. A telehealth service manages the GLP-1. Neither one may see the other's latest list. Nothing may be directly contraindicated — but nobody is watching the whole picture either.

Real questions people are asking

We pulled these from public forums to show you that this worry is normal and widespread. They're here as questions, not as evidence — no forum post can tell you whether a medication interaction happened.

"Anyone on both of these? Have you seen any difference in your anxiety/depression?" — r/Semaglutide

"I'm looking at starting Ozempic next week..." — r/OzempicForWeightLoss, asking whether antidepressants affect how well it works

"Should Ozempic work as I go up... or is my antidepressant likely to hinder the weight loss?" — r/OzempicForWeightLoss

These are personal concerns, not proof that any interaction occurred.

A forum answer cannot clear a combination, and one person's weight or mood result cannot predict yours. Use these questions to name the fear. Use the labels, studies, pharmacist, and prescribers to answer it.

If you're on a mental-health medicine, here's what actually matters when you pick a GLP-1 program

Answer capsule: For someone taking a mental-health medicine, the useful program differences are whether the intake captures every prescription and supplement, whether a licensed prescriber reviews that list, whether the product has current FDA prescribing information, and whether you can reach the care team between doses. Price still matters, but it should be shown separately from medication cost.

Everything above this line was about safety. This part is about picking a program, and we make money if you use some of the links here. We're telling you that up front so you can weigh it.

The medication name is not the only deciding factor. The current GLP-1 labels reviewed here do not list an antidepressant as a contraindication. What changes your experience is the exact product, the dose, and the program around it.

Two things to look for:

1. An intake that asks for your full medication list — including supplements — and a prescriber who reviews it. Not a checkbox. If you take lithium, a tricyclic, delayed-release Cymbalta, nefazodone, carbamazepine, or St. John's wort, somebody needs to see that before they prescribe.
2. A real route to clinical help between doses. Start and dose-increase periods are when nausea, vomiting, dehydration, and missed pills show up. That's exactly when you need an answer, not a sales inbox.

The one thing we're going to admit

We are not recommending a compounded GLP-1 on this page, and here's the honest reason.

Compounded drugs are not FDA-approved. FDA does not review them before marketing for safety, effectiveness, or quality. A compounded product can also use a different concentration, formulation, inactive ingredients, or route than an approved product.

This page works because we could read an FDA-approved label and quote the dosing, interaction, and monitoring rules back to you. A brand-name label does not automatically transfer to a compounded oral, sublingual, gum, drop, or injection.

Price is a real limit. It does not turn a compounded drug into a generic copy of an approved GLP-1. Start with the FDA-approved cash-pay and insurance comparison. If your clinician decides that an approved drug cannot meet a patient-specific medical need, FDA says the prescription should be filled by a state-licensed pharmacy. Get the exact formulation and instructions from that pharmacy.

If you take lithium or another medicine that needs close monitoring, a product with published prescribing information gives your care team a plan they can actually read. That's not marketing. It's the difference between a current label and an assumption.

Provider-stated versus what we verified

Where that lands

Ro is the first fit we'd check for this specific reader. It publicly lists FDA-approved GLP-1 options with prescribing information — including Wegovy tablets, Wegovy injection, Zepbound, and Foundayo — plus an insurance concierge and ongoing messaging. That lines up with the decision rules on this page: a label your pharmacist can read and a route back to the care team.

Pricing: Ro's live page showed $39 for the first month of membership, then $149 month-to-month or as low as $74 per month with an annual plan paid upfront. Medication is a separate charge. Dose-specific medication prices, manufacturer offers, and insurance results can change.

Sesame Care is the second option worth knowing about if choosing a specific provider matters more to you. Its live page showed a program starting at $59 per month with annual billing or $99 month-to-month, with medication charged separately.

Who should skip both: if cost is the binding constraint, start with the FDA-approved cost comparison. If you're not sure you want a GLP-1 at all yet, don't start with a provider — take the route-matching quiz at the bottom of this page instead.

Does that sound like your situation? If your prescriber has cleared the plan and you want a program built around FDA-approved medication with a label your pharmacist can read, check current pricing and availability at Ro.

What we still don't know

Answer capsule: We did not find a randomized trial that directly measured antidepressant blood levels during GLP-1 treatment. No antidepressant appears in the dedicated interaction-study lists in the GLP-1 labels reviewed here. Weight-management trials also screened out some people with recent psychiatric illness or certain weight-affecting medicines. The evidence rejects a blanket ban; it does not replace an individual medication review.

We'd rather show you the edges of what's known than pretend the map is complete.

What's genuinely unknown:

• We did not find a randomized trial measuring antidepressant blood levels before and during GLP-1 treatment. The absorption discussion is built from current labels, drug design, monitoring rules, and case evidence — not a head-to-head blood-level trial for every antidepressant.
• A compounded formulation cannot be assumed to act like an approved product. Different concentration, formulation, inactive ingredients, route, and instructions can change the answer. Compounded drugs are not FDA-approved and do not receive FDA premarket review for safety, effectiveness, or quality.
• People in active psychiatric crisis are underrepresented in pivotal weight-loss trials. Trial eligibility rules screened some of them out. So the safest thing to say about someone in a bad stretch is: that's a clinical conversation, not a website clearance.
• The 2022 observational study and the STEP post-hoc analysis answer different questions. Neither was designed to prove that one antidepressant causes or prevents one person's GLP-1 weight result.
• Labels change. Foundayo's label was new in April 2026. Wegovy's current label was revised in February 2026. Oral Ozempic tablets and the current Rybelsus label were revised in January 2026. That is why every table on this page carries a date.

What we're confident about:

• No antidepressant appears in the contraindications sections of the current U.S. labels reviewed for this page
• Wegovy, Rybelsus, and Ozempic tablets have the same 30-minute morning wall before other oral medicines
• The injections do not have that pill-spacing rule; Saxenda is daily and the others named in that row are weekly
• Foundayo's CYP3A4 rules include a 9 mg cap with strong inhibitors and avoidance of strong inducers
• Published lithium cases support baseline review and more frequent, prescriber-set monitoring
• Contrave is not the only non-GLP-1 weight-loss drug with an MAOI restriction

Frequently asked questions

Can you take Ozempic and Zoloft together? The current Ozempic injection label does not list sertraline as a contraindication, and the injection has no 30-minute pill-spacing rule. Ozempic tablets are different: take the semaglutide tablet first and wait at least 30 minutes before Zoloft or any other oral medicine.

Does Wegovy interact with Lexapro? No direct Lexapro contraindication appears in the current Wegovy label. If you use Wegovy injection, there is no 30-minute pill-spacing rule. If you use Wegovy tablets and take Lexapro in the morning, take Wegovy first and wait at least 30 minutes.

Can you take Zepbound with Wellbutrin? Bupropion does not appear as a contraindication in the current Zepbound label. Bupropion's own restrictions — including seizure disorder, anorexia nervosa or bulimia history, and another bupropion product — still apply.

Can a GLP-1 cause serotonin syndrome with an antidepressant? No class-wide GLP-1-and-antidepressant serotonin-syndrome interaction appears in the current labels reviewed here, and GLP-1 drugs are not serotonergic. Your full list can still contain other serotonin-raising combinations, so have the whole list checked.

Do I need to space out my GLP-1 shot and my antidepressant? No 30-minute spacing rule applies to the injections. Keep your antidepressant at its prescribed time. Closely monitored oral medicines such as lithium still need their own plan.

Which GLP-1 pills have the 30-minute rule? Wegovy tablets, Rybelsus, and Ozempic tablets. Take the tablet on an empty stomach in the morning with up to 4 ounces of water, then wait at least 30 minutes before food, other drinks, or another oral medicine.

Can I take Foundayo with an SSRI? No SSRI appears as a contraindication in the Foundayo label. Foundayo did not inhibit or induce CYP2D6 in vitro, but it still delays stomach emptying. The strong CYP3A4 issues on this page involve nefazodone, St. John's wort, and carbamazepine.

Is St. John's wort okay with a GLP-1? It does not create the Foundayo-style CYP problem with the peptide GLP-1 products in this guide. With Foundayo, FDA lists St. John's wort as a strong CYP3A inducer and the label says to avoid strong inducers.

Can you take a GLP-1 if you're on lithium? It is not listed as a prohibited combination, but published cases describe higher lithium levels and toxicity after semaglutide and after a switch to tirzepatide. Ask for baseline lithium, kidney function, and hydration review, then a prescriber-set plan for more frequent levels after starts, switches, and dose increases.

Will antidepressants stop my GLP-1 from working? No universal blocking effect has been established. A 2022 observational study found less weight loss in two antidepressant cohorts, while a published STEP analysis found substantial semaglutide weight loss in antidepressant users. Do not stop a working antidepressant to chase a theory.

What should I do if I throw up after taking my antidepressant? Don't automatically retake it. Call the pharmacy that filled it and give the exact drug, release form, time since the dose, and whether you saw the pill. There is no universal retake rule.

Do telehealth GLP-1 providers reject you for taking an antidepressant? An antidepressant alone is not a contraindication in the GLP-1 labels reviewed here. Program rules and clinical decisions differ. Give the exact, complete list anyway — including supplements and release forms.

Should I stop my antidepressant to lose weight faster? No. The large comparative study found small average differences between common antidepressants, and stopping can bring withdrawal and relapse. Any change needs a prescriber-led plan.

Can I take a GLP-1 if I'm on an MAOI? No MAOI appears as a GLP-1 contraindication in the labels reviewed here, but MAOIs have many other restrictions. Contrave, Qsymia, and phentermine are each contraindicated during MAOI use and within 14 days after stopping one. Have a pharmacist review the whole list.

Are compounded GLP-1 interactions the same as Wegovy or Zepbound? Don't assume so. Compounded drugs are not FDA-approved, and their concentration, formulation, inactive ingredients, route, and instructions can differ. Ask the dispensing pharmacy for the exact product information.

Should my GLP-1 prescriber talk to my psychiatrist? It helps most when mood is unstable, either medicine changed recently, lithium or another closely monitored drug is involved, or neither prescriber has the full list. At minimum, ask which clinician owns each part of the monitoring plan.

How we made this page

Who: The Weight Loss Provider Guide Research Team. Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers. We don't have a doctor on staff and we're not pretending otherwise — this page is built from primary documents, and we show you every one so you can check us.

How: We read the current U.S. prescribing information for each product named here, pulled the dosing and interaction rules from the relevant sections, cross-referenced FDA's current CYP examples, read the antidepressant and non-GLP-1 weight-loss labels for the specific medicines that came up, opened the SURMOUNT-1 protocol, and reviewed the primary studies on lithium, psychiatric safety, antidepressant weight differences, and GLP-1 weight outcomes. Provider prices and features are labeled as provider-stated unless we independently verified more than the live page.

Why: Because "generally safe, ask your doctor" isn't an answer. It's a deferral. If you're standing in your kitchen holding two prescriptions at 6 a.m., you need to know which one goes first — and most pages were not telling you.

Corrections: If something here is wrong, tell us. We'll fix it and note the change and the date. Report a correction.

Sources

Current FDA prescribing information and interaction tables

• Wegovy injection and tablets prescribing information, revised 02/2026 — dosing, oral-medication monitoring, contraindications, adverse reactions
• Rybelsus and Ozempic tablets prescribing information, revised 01/2026 — 30-minute rule and oral-medication warning
• Ozempic injection prescribing information, revised 05/2026
• Zepbound prescribing information, revised 02/2026
• Mounjaro prescribing information, revised 01/2026
• Saxenda prescribing information, revised 02/2026
• Foundayo prescribing information, initial U.S. approval 2026 — CYP3A4 dose rules, gastric emptying, interaction-study results
• FDA examples of drugs that interact with CYP enzymes and transporters
• FDA review of suicidal thoughts and behavior with GLP-1 receptor agonists, January 2026

Antidepressant and non-GLP-1 weight-loss labels

• Cymbalta prescribing information — enteric coating and altered gastric-motility caution
• Wellbutrin SR prescribing information, revised 11/2025 — seizure and eating-disorder contraindications
• Nortriptyline prescribing information — plasma-level monitoring above 100 mg/day
• Contrave prescribing information — other bupropion products, MAOIs, seizure and eating-disorder contraindications
• Qsymia prescribing information — MAOI contraindication
• Phentermine prescribing information — MAOI contraindication
• Venlafaxine extended-release prescribing information — weight-loss agents including phentermine

Trials and studies

• SURMOUNT-1 protocol, NCT04184622 — medication exclusion list and SSRI note
• STEP 1 trial record, NCT03548935 — psychiatric eligibility context
• Durell N et al. Effect of Antidepressants on GLP-1 Receptor Agonist-Related Weight Loss, 2022
• Kushner RF et al. Semaglutide 2.4 mg efficacy and safety by baseline antidepressant use
• Petimar J et al. Medication-induced weight change across common antidepressant treatments, 2024
• Al-Soleiti M et al. Lithium Toxicity and Altered Clearance Following Initiation of Semaglutide, 2025
• Lithium toxicity following a semaglutide-to-tirzepatide switch, 2026

Compounding and provider verification

• FDA's concerns with unapproved GLP-1 drugs used for weight loss
• Ro weight-loss program pricing
• Sesame online weight-loss program

Last verified: August 7, 2026 · Next full evidence review: November 7, 2026

Still not sure which GLP-1 program is right for you? Take our free 60-second matching quiz.

You've got the safety answer. The next question is which route actually fits — injection or pill, insurance or cash pay, and what happens if you need help between doses.

→ Get My Personalized GLP-1 Action Plan

No email required to see your result. The quiz compares treatment routes. It does not clear any medication combination — that's still a conversation with your prescriber or pharmacist.

This page is general information, not medical advice. It cannot tell you whether a specific medication combination is right for you. Never start, stop, move, repeat, or change the dose of an antidepressant or GLP-1 on your own.